会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • 1-N-Aminobenzimidazole derivatives
    • 1-N-氨基苯并咪唑衍生物
    • US20050148634A1
    • 2005-07-07
    • US10507361
    • 2003-03-28
    • Masaaki NagasawaHiroyasu NishiokaKazuyasu AsamiNaoyoshi MiuraHideki NakamuraHitoshi Morita
    • Masaaki NagasawaHiroyasu NishiokaKazuyasu AsamiNaoyoshi MiuraHideki NakamuraHitoshi Morita
    • A61P1/04A61P43/00C07D401/12A61K31/4439C07D43/02
    • C07D401/12C07D471/04C07D495/04
    • Provided are 1-N-aminobenzimidazole derivatives represented by the following formula (I): wherein R1 and R2 each represents a substituted or unsubstituted alkyl group or the like, R3, R5 and R6 each represents an alkyl group, alkoxy group, hydrogen atom or the like, R4 represents a substituted or unsubstituted alkyl group or the like, A represents a benzene ring or the like, B represents a hydrogen atom or the like, an n stands for an integer of from 0 to 2, or salts thereof; and medicines containing them. The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the risk of induction of an interaction or a cancer caused by induction of the CYP1A family. Accordingly, they are useful as peptic ulcer therapeutic agents which are safe and surely bring about therapeutic effects.
    • 提供由下式(I)表示的1-N-氨基苯并咪唑衍生物:其中R 1和R 2各自表示取代或未取代的烷基等,R R 5,R 5和R 6各自表示烷基,烷氧基,氢原子等,R 4, SUP>表示取代或未取代的烷基等,A表示苯环等,B表示氢原子等,n表示0〜2的整数,或其盐; 和含有它们的药物。 尽管CYP2C19活性存在个体差异,但是本发明的化合物(I)不会在治疗效果上产生太多的个体差异。 在相同剂量下,它们可以为所有患者带来适当的治疗效果。 此外,它们诱导由CYP1A家族诱导引起的相互作用或癌症的风险较低。 因此,它们可用作消化性溃疡治疗剂,其是安全的并且确实具有治疗效果。